Integra LifeSciences Holdings Corporation — Q2 2022 Form 10-Q Summary
Business Context and Reporting Period
Integra is a global medical technology company operating through two reportable segments: Codman Specialty Surgical, focused on neurosurgery and surgical instruments, and Tissue Technologies, focused on wound reconstruction, regenerative tissue, and peripheral nerve repair. This unaudited Form 10-Q covers the three and six months ended June 30, 2022, compared with the corresponding 2021 periods.
Financial Performance and Key Metrics
| Metric | Q2 2022 | Q2 2021 | Six Months 2022 | Six Months 2021 |
|---|---|---|---|---|
| Revenue | $397.8 million | $390.0 million | $774.5 million | $750.1 million |
| Gross profit | $249.4 million | $238.7 million | $483.5 million | $453.0 million |
| Gross margin | 62.7% | 61.2% | 62.4% | 60.4% |
| Operating income | $59.9 million | $51.9 million | $106.0 million | $82.6 million |
| Approximate operating margin | 15.0% | 13.3% | 13.7% | 11.0% |
| Net income | $44.8 million | $35.1 million | $77.7 million | $80.5 million |
| Diluted EPS | $0.54 | $0.41 | $0.93 | $0.94 |
Q2 revenue increased 2.0%, while six-month revenue increased 3.3%. The six-month comparison was affected by a $42.2 million gain from the 2021 sale of the Extremity Orthopedics business. Excluding that gain, management stated that six-month net income increased year over year.
- Codman Specialty Surgical revenue was $257.9 million in Q2 and $505.2 million for the six months, up 0.4% and 1.4%, respectively.
- Tissue Technologies revenue was $140.0 million in Q2 and $269.3 million for the six months, up 5.1% and 6.9%, respectively.
- Unfavorable foreign exchange reduced revenue by approximately $10.3 million in Q2 and $14.9 million for the six months.
- Research and development expense increased to $25.6 million in Q2 and $49.7 million for the six months, reflecting product development, clinical studies, and EU Medical Device Regulation compliance.
- The effective tax rate was 13.2% in Q2 and 14.5% for the six months, benefiting from excess tax benefits related to stock compensation.
Cash Flow, Liquidity, Debt, and Capital Allocation
- Cash provided by operating activities was $110.8 million for the six months, compared with $160.4 million in 2021.
- Capital expenditures were $18.7 million. Investing cash flow was negative $18.6 million, compared with negative $125.5 million in 2021, which included the ACell acquisition and proceeds from the Extremity Orthopedics divestiture.
- Financing cash flow was negative $146.6 million, principally due to a $125.0 million accelerated share repurchase and $23.2 million of cash taxes paid on net equity settlements.
- Cash and cash equivalents declined to $447.2 million from $513.4 million at December 31, 2021. Approximately $302.6 million was held by non-U.S. subsidiaries and was available for use outside the United States.
- Working capital was $841.8 million at June 30, 2022, compared with $813.7 million at year-end 2021.
- Debt comprised approximately $870.3 million under the senior credit facility, $112.5 million under the securitization facility, and $565.9 million of convertible securities, for total reported borrowings of approximately $1.55 billion. Approximate debt less cash was $1.10 billion.
- The senior credit facility matures in February 2025, the securitization facility matures in May 2024, and the convertible notes mature in August 2025. The company was in compliance with its debt covenants at June 30, 2022.
- Management believes cash and available borrowings are sufficient to fund operations and capital expenditures for the foreseeable future and forecasts covenant compliance for the next twelve months.
Material Changes Versus the Prior Comparable Period
- Revenue and gross margin improved, with gross margin expanding 150 basis points in Q2 and 200 basis points for the six months. Management attributed the improvement partly to reduced ACell inventory step-up amortization.
- Operating income increased 15.5% in Q2 and 28.5% for the six months, despite increased research and development spending.
- Six-month net income declined 3.4% because the prior-year period included the $42.2 million Extremity Orthopedics sale gain; the current period had no comparable gain.
- Operating cash flow decreased by $49.5 million, primarily because accounts receivable and inventory increased and accrued liabilities declined.
- The company repurchased $125.0 million of stock under an accelerated share repurchase agreement and authorized a new $225.0 million repurchase program expiring in December 2024.
- On May 20, 2022, the company agreed to sell its non-core traditional wound care business to Gentell for approximately $28.8 million, including $27.8 million in cash and up to $1.0 million of contingent consideration. Closing was expected around August 31, 2022, subject to customary conditions.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide clear numerical revenue or earnings guidance. Management expects sales and earnings over the next twelve months to support debt covenant compliance.
- COVID-19 remains a risk through procedure delays or cancellations, hospital staffing shortages, supply-chain disruption, higher freight and labor costs, and reduced customer spending. Inflation and recessionary conditions could further affect demand.
- The company is closing a manufacturing facility in France, transferring production to Switzerland, and outsourcing certain transactional back-office activities. Restructuring charges for the six months were $3.4 million, and $6.7 million remained accrued at June 30, 2022.
- EU MDR compliance costs were $19.8 million for the six months, compared with $9.2 million in the prior-year period.
- The FDA continues to have open concerns regarding quality systems at the TEI Boston facility. The filing states that the Warning Letter and 2021 Form 483 do not currently restrict manufacturing or shipments, but additional regulatory action could materially affect the business. Products manufactured at the facility represented approximately 6.0% of six-month consolidated revenue.
- The company faces contingent consideration obligations, including up to $100.0 million related to the ACell acquisition and up to $25.5 million related to Arkis. The estimated ACell contingent consideration liability was $18.1 million at June 30, 2022.
- Foreign exchange and variable-rate debt remain material exposures. The company uses currency and interest-rate derivatives; total interest-rate swap notional amounts were $1.8 billion, with $875.0 million effective at quarter-end.
- Ordinary-course litigation, product liability claims, tax matters, FDA compliance, leases, pensions, and other contingencies are disclosed. Management does not expect these matters to have a material adverse effect, but acknowledges that particular periods could be materially affected.
Most Important Facts for Investors to Verify
- Whether the traditional wound care divestiture closed on expected terms and how the transaction affects revenue, margins, and working capital.
- Whether foreign exchange pressure, inflation, supply constraints, and hospital staffing shortages continue to affect organic growth and gross margin.
- Progress and potential financial impact of FDA remediation at the TEI Boston facility.
- Debt covenant headroom, refinancing plans for 2024–2025 maturities, and sensitivity to higher interest rates.
- Cash conversion, particularly the effects of inventory and accounts receivable growth on operating cash flow.
- The sustainability of the lower effective tax rate, including the effect of stock-compensation tax benefits.
- Future payments under ACell, Arkis, and other contingent consideration arrangements.
- Execution of restructuring, manufacturing transfers, outsourcing, product launches, and EU MDR compliance initiatives.